Centerwatch.com produced an interesting article on the implementation of new strategies to improve drug developer’s access to comparator drugs for clinical testing. The article brings to light the difficulty of obtaining comparator drugs, with the Tufts Center for...
On September 10, 2013, the Tufts Center for the Study of Drug Development released a report concerning the leading causes of failures in drug development. Based on a study of products that entered clinical development from 2000 through 2009, the study found that Phase...
Research conducted by the Tufts Center for the Study of Drug Development (CSDD) found that protocol complexity correlates with longer clinical study times and poorer patient recruitment. Therefore, drug development companies are working to increase clinical trial...
In 2012, an all-time high of 28,000 principal investigators participated in FDA regulated research, according to a study in the March/April Tufts Center for the Study of Drug Development (CSDD) Impact Report. However, compound annual growth in the number of active...
As reported in Outsourcing Pharma, a new study conducted by the Tufts Center for the Study of Drug Development shows that CRAs (clinical research associates)spend less than half their time doing on-site monitoring tasks. This report included close to 4,000 CRAs from...
Single IRB – A Guide to the Common Rule sIRB Mandate
The sIRB requirement is active. Is your study affected?
